The different approaches to array CGH provide different levels of performance. In other words some approaches are more suitable for particular applications than others. For instance it is much easier to detect large increases in copy number associated with the amplification of a genomic region than single-copy losses or gains. Aberrations affecting an extended genomic region spanning multiple array elements are easier to detect than focal events. Measurements on cell lines are most likely the least difficult because the isolation of good quality DNA is an easy and straightforward procedure. Fresh or frozen tumor tissues are more challenging because of the risk of normal cells being included.
Formalin-fixed paraffin-embedded (FFPE) tissue used to present the greatest challenge. Data obtained from such specimens can range from excellent (i.e. indistinguishable from fresh tissue) to unusable. Simple checks such as fragment size distribution of the isolated DNA have not been reliable predictors of performance. One of the difficulties may be determining accurately the amount of DNA present in a sample; contaminants from the tissue section or isolation procedure may interfere with the fluorimetry and absorbance measurements.
The ULS technology is ideal for labeling DNA extracted from FFPE material because of its independence of fragment length.
Start from the beginning: the starting material
One of the main advantages of ULS is its independence of the nature of the starting material.
There are four main starting points depending on the quality of the starting material and whether you require amplification or not:
Important: Amplification is needed as soon as the amount of sample available does not match the amount needed for hybridization, since unlike enzymatic labeling methods our ULS labeling technology does not augment the amount of starting material.
The Platforms
One of Kreatech's key strengths is offering you the ability to label genomic DNA directly without having to worry about the platform. We offer you a labeling technology and hybridization procedures optimized for both BAC and Oligo platforms. Both of which have been extensively tested at Kreatech. Click below for more information:
The different approaches to array CGH provide different levels of performance. In other words some approaches are more suitable for particular applications than others. For instance it is much easier to detect large increases in copy number associated with the amplification of a genomic region than single-copy losses or gains. Aberrations affecting an extended genomic region spanning multiple array elements are easier to detect than focal events. Measurements on cell lines are most likely the least difficult because the isolation of good quality DNA is an easy and straightforward procedure. Fresh or frozen tumor tissues are more challenging because of the risk of normal cells being included.
Formalin-fixed paraffin-embedded (FFPE) tissue used to present the greatest challenge. Data obtained from such specimens can range from excellent (i.e. indistinguishable from fresh tissue) to unusable. Simple checks such as fragment size distribution of the isolated DNA have not been reliable predictors of performance. One of the difficulties may be determining accurately the amount of DNA present in a sample; contaminants from the tissue section or isolation procedure may interfere with the fluorimetry and absorbance measurements.
The ULS technology is ideal for labeling DNA extracted from FFPE material because of its independence of fragment length.
Start from the beginning: the starting material
One of the main advantages of ULS is its independence of the nature of the starting material.
There are four main starting points depending on the quality of the starting material and whether you require amplification or not:
Important: Amplification is needed as soon as the amount of sample available does not match the amount needed for hybridization, since unlike enzymatic labeling methods our ULS labeling technology does not augment the amount of starting material.
The Platforms
One of Kreatech's key strengths is offering you the ability to label genomic DNA directly without having to worry about the platform. We offer you a labeling technology and hybridization procedures optimized for both BAC and Oligo platforms. Both of which have been extensively tested at Kreatech. Click below for more information: